Traditional Chinese medicine compound composition for treating kidney deficiency, blood stasis and phlegm type postmenopausal female coronary heart disease and preparation method thereof

Abstract

The invention relates to the technical field of traditional Chinese medicine compound compositions, in particular to a traditional Chinese medicine composition for treating kidney deficiency, blood stasis and phlegm type postmenopausal female coronary heart disease. According to the technical scheme, the preparation method comprises the following steps: taking the following raw materials in parts by mass: 20-30 parts of prepared rehmannia root, 10-20 parts of Chinese yam, 5-15 parts of dogwood, 5-15 parts of rhizoma alismatis, 10-20 parts of moutan bark, 10-20 parts of poria cocos, 3-9 parts of turmeric, 5-10 parts of curcuma zedoary and 10-20 parts of verbena. The preparation method comprises the following steps: putting the medicinal materials into a clean container, washing with clear water, putting into a marmite or a ceramic pot, adding 5 times by weight of water, boiling with big fire, decocting with small fire for 1-2 hours, and filtering out medicine residues with a filter screen or gauze after the decoction is finished, thereby obtaining the liquid medicine. Adding clear water with the same amount as that in the first time into medicine residues again, and decocting according to the method. And merging the liquid medicines obtained by decocting twice, adding ethanol with the volume concentration of 80% for treatment, standing, filtering and recycling, and concentrating at 60 DEG C until the relative density is 1.30-1.36 to obtain the extract. The pharmaceutical composition and a pharmaceutically acceptable carrier are prepared into medicines in dosage forms such as ointment, oral liquid, granules and the like.

Description

Technical Field

[0001] The invention relates to the technical field of Chinese medicinal compound compositions, and more particularly to a Chinese medicinal compound composition for treating coronary heart disease of postmenopausal women of kidney deficiency, blood stasis and phlegm turbidity type and a preparation method thereof. Background Art

[0002] Coronary heart disease, the full name of which is coronary atherosclerotic heart disease, is a heart disease caused by atherosclerosis of the coronary arteries, which leads to stenosis or obstruction of the blood vessel lumen, causing myocardial ischemia, hypoxia or necrosis. The main clinical manifestations are chest tightness and oppression. According to the "Summary of China's Cardiovascular Health and Disease Report 2022", the prevalence and mortality of cardiovascular disease (CVD) in my country are in a continuous upward stage. Coronary heart disease is a major public health issue in my country, which requires continuous attention and effective prevention and treatment measures.

[0003] In recent years, research reports on cardiovascular diseases in my country have pointed out that the mortality rate of coronary heart disease in my country has increased year by year, and the mortality rate of coronary heart disease in women has contributed a large part to it, which is particularly significant in postmenopausal women. Studies have shown that estrogen can maintain the stability of vascular endothelial function from damage, so premenopausal women have always been considered a group with a low incidence of coronary heart disease. However, with the menopause of women, the cessation of their ovarian function reduces the protective effect of estrogen on cardiovascular function. Therefore, menopause is an independent risk factor for cardiovascular disease in women. The clinical symptoms of female patients with coronary heart disease are often atypical, highly disturbing, easily missed, and have a worse prognosis than men. Male patients with coronary heart disease often present with chest pain as the main symptom, while women are mostly back pain and sweating, and the incidence of chest pain is lower, often accompanied by shortness of breath and fatigue. In addition, the extensive and complicated clinical manifestations after menopause are also easy to interfere with correct and timely diagnosis.

[0004] The treatment of coronary heart disease in postmenopausal women is still based on drug therapy, combined with some non-drug interventions such as improving the patient's lifestyle. Although Western medicine has the advantages of rapid onset and obvious efficacy in the treatment of coronary heart disease, there are also some clinical pain points. For example, antiplatelet aggregation drugs may irritate the gastrointestinal tract and cause gastrointestinal symptoms, and in severe cases, gastrointestinal bleeding may occur; the incidence of myolysis and liver damage will gradually accumulate after long-term use of statins; nitrate drugs, long-term use may lead to the development of drug resistance, affecting the efficacy of the drug, and some patients may experience central nervous system side effects such as dizziness and headache; although estrogen supplementation therapy can reduce low-density lipoprotein and reduce the incidence of cardiovascular events, long-term use of estrogen may increase the risk of endometrial cancer and breast cancer; various Western medicines may compete with CYP450 digestive enzymes, resulting in weakening or excessive enhancement of their own effects. In summary, due to the side effects that Western medicine may bring, the clinical treatment effect of patients is not good. Based on the above pain points, it is essential to find a safe and effective Chinese medicine supplementary therapy for coronary heart disease in postmenopausal women.

[0005] Traditional Chinese medicine has the characteristics of high safety, few side effects, and multi-target and multi-pathway synergistic effects. It is also an advantageous entry point for Chinese medicine to treat coronary heart disease. Liuwei Dihuang Fang is a commonly used and effective drug for the treatment of coronary heart disease, mainly suitable for coronary heart disease in postmenopausal women with kidney yin deficiency. However, the existing Liuwei Dihuang Fang has a weak effect on promoting qi and activating blood circulation, and postmenopausal women are more prone to poor qi and blood circulation due to changes in hormone levels in the body. Therefore, it is an urgent problem for technical personnel in this field to provide a drug for the treatment of coronary heart disease that takes into account the effects of promoting qi and activating blood circulation. Summary of the invention

[0006] In view of this, the present invention provides a Chinese medicine compound preparation for treating coronary heart disease in postmenopausal women of kidney deficiency, blood stasis and phlegm turbidity type, which can enhance the function of promoting qi and activating blood circulation, thereby better improving the clinical symptoms of patients such as chest tightness and chest pain.

[0007] In order to achieve the above object, the present invention adopts the following technical solution: A Chinese medicinal compound for treating coronary heart disease of postmenopausal women with kidney deficiency, blood stasis and phlegm turbidity type, comprising the following raw materials in parts by weight: 20-30 parts of Rehmannia root, 10-20 parts of Chinese yam, 5-15 parts of Cornus officinalis, 5-15 parts of Alisma orientalis, 10-20 parts of Paeonia suffruticosa, 10-20 parts of Poria cocos, 3-9 parts of Turmeric, 5-10 parts of Curcuma zedoaria, 10-20 parts of Verbena officinalis Further, a Chinese medicine compound for treating coronary heart disease in postmenopausal women of kidney deficiency, blood stasis and phlegm turbidity type: 21-25 parts of Rehmannia root, 11-15 parts of Dioscorea opposita, 6-10 parts of Cornus officinalis, 6-10 parts of Alisma orientalis, 11-15 parts of Paeonia suffruticosa, 11-15 parts of Poria, 4-6 parts of Curcuma longa, 6-9 parts of Curcuma zedoaria, and 11-15 parts of Verbena officinalis.

[0008] A method for preparing a Chinese medicine compound composition for treating hypertension of kidney deficiency, blood stasis and phlegm turbidity type comprises the following steps: Take Radix Rehmanniae Preparata, Dioscorea Oppositae, Fructus Corni, Rhizoma Alismatis, Cortex Moutan, Poria, Rhizoma Curcumae, and Verbena according to the above mass fractions, put the medicinal materials into a clean container, rinse with clean water, and remove impurities on the surface. For some larger medicinal materials, appropriate cutting or crushing can be performed to improve the extraction efficiency. Put the cleaned medicinal materials into a casserole or ceramic pot, add 5 times the weight volume of water, boil over high heat first, and then decoct over low heat for 1 to 2 hours. After the decoction is completed, filter out the medicinal residue with a filter screen or gauze to obtain a medicinal liquid. Add the medicinal residue to the same amount of clean water as the first time again, and decoct according to the above method. Combine the medicinal liquids obtained by the two decoctions, add ethanol with a volume concentration of 80%, let it stand, filter and recover it here, and concentrate it at 60°C to a relative density of 1.30 to 1.36 to obtain an extract. Prepare the medicine in the form of ointment, oral liquid, granules, etc. with a pharmaceutically acceptable carrier.

[0009] In the present invention, the pharmacological effects of each raw material and the formula are as follows: the Radix Rehmanniae in the formula directly enters the kidney meridian, nourishes yin and blood, benefits the kidney and replenishes essence. The formula reuses the Radix Rehmanniae as the main ingredient, which can nourish the liver and kidney; the yam is mild in nature and sweet in taste, and enters the spleen, lung and kidney meridians; the Cornus officinalis is slightly warm in nature, sour and astringent in taste, and enters the liver and kidney meridians. The two medicines are assistant medicines, and are matched with the Rehmanniae. On the one hand, they can enhance the effect of nourishing yin and tonifying the kidney, and on the other hand, they can also help the body better absorb and utilize the nourishing ingredients and reduce the loss of essence through the effects of tonifying the spleen and consolidating essence. Peony bark is bitter and pungent, slightly cold in nature, and enters the heart, liver, and kidney meridians. It has the effects of clearing heat and cooling blood, promoting blood circulation and removing blood stasis, and relieving deficiency fever. It calms liver fire while promoting blood circulation and removing blood stasis, improving blood circulation, and alleviating blood stasis symptoms; Poria cocos and Alisma orientalis are sweet and light in taste, and enter the kidney meridian together, which has the function of promoting water and dampness, and can help regulate the body's water balance and indirectly improve the blood supply to the heart; the three medicines are adjuvants; turmeric and curcuma are bitter and pungent in nature, warm in nature, and enter the spleen and liver meridians, and have the effects of breaking blood, promoting qi, and relieving pain. The main ingredient of turmeric, curcumin, has antioxidant and anti-inflammatory effects, which help protect the cardiovascular system, reduce myocardial damage, and improve heart function. Curcumin also has an anticoagulant effect, can prevent thrombosis, and has a positive effect on patients with coronary heart disease. Verbena is cool in nature and bitter in taste, and enters the liver and spleen meridians. It has the effects of clearing away heat and detoxifying, promoting blood circulation and dispersing blood stasis. Turmeric, Curcuma zedoaria and Verbena are used as the guiding drugs in the prescription, which not only enhance the effect of promoting blood circulation and removing blood stasis of the whole prescription, but also neutralize the other warm drugs in the prescription with the cold nature of Verbena to prevent the tonic drugs from being too much and causing greasy stomach upset. The whole prescription is both tonic and purgative, treating both the symptoms and the root causes, preventing the disease from changing, and playing the effect of nourishing yin and kidney, and removing phlegm and blood stasis. Specific embodiments

[0010] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0011] The invention discloses a Chinese medicinal compound composition for treating coronary heart disease of postmenopausal women of kidney deficiency, blood stasis and phlegm turbidity type. The clinical manifestation of the patients with this disease is atypical chest pain: pain in the precordial area occurs after physical activity or emotional excitement, which can radiate to the left shoulder, arm, neck, mandible, etc., or paroxysmal colic or squeezing pain, which can be relieved by rest or taking nitroglycerin, accompanied by ischemic changes in electrocardiogram, and obvious coronary artery stenosis can be seen in CTA or coronary angiography.

[0012] The present invention provides a Chinese medicine compound composition for treating coronary heart disease of postmenopausal women of kidney deficiency, blood stasis and phlegm turbidity type, which is composed of the following parts by mass: 20-30 parts of Rehmannia root, 10-20 parts of Chinese yam, 5-15 parts of Cornus officinalis, 5-15 parts of Alisma orientalis, 10-20 parts of Paeonia suffruticosa, 10-20 parts of Poria, 3-9 parts of Curcuma longa, 5-10 parts of Curcuma zedoaria, and 10-20 parts of Verbena officinalis.

[0013] Further, a Chinese medicine compound for treating coronary heart disease in postmenopausal women of kidney deficiency, blood stasis and phlegm turbidity type: 20-25 parts of Rehmannia root, 10-15 parts of Dioscorea opposita, 5-10 parts of Cornus officinalis, 5-10 parts of Alisma orientalis, 10-15 parts of Paeonia suffruticosa, 10-15 parts of Poria, 3-6 parts of Curcuma longa, 6-9 parts of Curcuma zedoaria, and 10-15 parts of Verbena officinalis.

[0014] A method for preparing a Chinese medicine compound composition for treating hypertension of kidney deficiency, blood stasis and phlegm turbidity type comprises the following steps: Take Radix Rehmanniae Preparata, Dioscorea Oppositae, Fructus Corni, Rhizoma Alismatis, Cortex Moutan, Poria, Rhizoma Curcumae, and Verbena according to the above mass fractions, put the medicinal materials into a clean container, rinse with clean water, and remove impurities on the surface. For some larger medicinal materials, appropriate cutting or crushing can be performed to improve the extraction efficiency. Put the cleaned medicinal materials into a casserole or ceramic pot, add 5 times the weight volume of water, boil over high heat first, and then decoct over low heat for 1 to 2 hours. After the decoction is completed, filter out the medicinal residue with a filter screen or gauze to obtain a medicinal liquid. Add the medicinal residue to the same amount of clean water as the first time again, and decoct according to the above method. Combine the medicinal liquids obtained by the two decoctions, add ethanol with a volume concentration of 80%, let it stand, filter and recover it here, and concentrate it at 60°C to a relative density of 1.30 to 1.36 to obtain an extract. Prepare the medicine in the form of ointment, oral liquid, granules, etc. with a pharmaceutically acceptable carrier.

[0015] The clinical effect of the Chinese medicine compound composition for treating coronary heart disease of postmenopausal women of kidney deficiency, blood stasis and phlegm turbidity type according to the present invention is illustrated below by clinical trial examples.

[0016] Clinical data: Research subjects: A total of 75 postmenopausal female patients with coronary heart disease of kidney deficiency, blood stasis and phlegm turbidity type who were admitted to Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine and Lishui District Hospital of Traditional Chinese Medicine from January 2023 to April 2024 were selected as research subjects and randomly divided into 3 groups: control group (Western medicine treatment group alone), treatment group 1 (Western medicine + Liuwei Dihuang prescription treatment group), and treatment group 2 (Western medicine + Ziyin Xiezhuo prescription treatment group), with 25 cases in each group.

[0017] Inclusion criteria: 1. Western medicine diagnostic criteria: in line with the American Heart Association's diagnostic criteria for coronary heart disease 2. TCM diagnostic criteria: Two TCM cardiovascular specialists with the title of deputy chief physician or above will make syndrome differentiation. In case of disagreement, they will be resolved through negotiation. Those who cannot reach a consensus will be excluded. TCM syndrome differentiation diagnostic criteria refer to the "Guidelines for Clinical Research of New Chinese Medicines (Trial)": Postmenopausal women with kidney deficiency and blood stasis: chest tightness or stabbing pain, soreness of waist and knees, night fever, night sweats, dark red tongue, and thin pulse.

[0018] Inclusion criteria: (1) meeting the above Western medicine and traditional Chinese medicine diagnostic criteria; (2) coronary angiography showed a diameter stenosis of ≥50% at the lesion site; (3) patients and their families agreed to participate in this study and signed the informed consent form.

[0019] Exclusion criteria: (1) Patients who are unable to cooperate with Chinese medicine treatment; (2) Patients with severe liver and kidney dysfunction; (3) Patients with malignant tumors; (4) Patients who cannot tolerate dual antiplatelet drug treatment; (5) Patients with allergic constitution or allergy to experimental drugs; (6) Patients with severe bleeding; (7) Patients with familial hypercholesterolemia; (8) Patients with rheumatic immune system diseases; (9) Patients who need to adjust the lipid-lowering regimen during the study, such as changing the type of statin, adjusting the treatment dose, and combining with other lipid-lowering drugs.

[0020] result (1) Comparison of blood lipid levels among the three groups of patients before and after treatment There were no significant differences in general condition, TC, HDL-C, and LDL-C levels between the control group and treatment group 1, and between treatment group 1 and treatment group 2 before treatment ( P >0.05), indicating that there was no significant difference in the total score of TCM syndromes between the two groups before treatment, and they were comparable. After treatment, the TC of the control group was (4.16±0.78), HDL-C was (0.95±0.20), and LDL-C was (2.00±0.72), while the TC of the treatment group was (3.83±0.62), HDL-C was (0.97±0.19), and LDL-C was (1.70±0.50). After paired sample t test, the two groups P The values ​​were all <0.01, indicating that the differences between the two groups after treatment were statistically significant. The blood lipid efficacy between the two groups after treatment was compared by two independent sample t-tests. P =0.000 (P<0.01), the difference was statistically significant. It means that both the control group and the treatment group 2 can reduce blood lipids, and the treatment group 2 is better than the control group. It shows that the Ziyin Xiezhuo prescription is significantly better than the simple Western medicine control group in reducing blood lipids in the treatment of postmenopausal women with coronary heart disease of kidney deficiency, blood stasis and phlegm turbidity.

[0021] After treatment, the LDL-C in treatment group 1 was (1.82±0.65), and that in treatment group 2 was (1.70±0.50). Paired sample t test showed that the blood lipids in the two groups after treatment were PThe values ​​were all <0.01, and the differences between the two groups after treatment were statistically significant. The blood lipid efficacy between the two groups after treatment was compared by two independent sample t-tests. P =0.076( P >0.05), the difference was not statistically significant. This indicates that the lipid-lowering effect of treatment group 1 is equivalent to that of treatment group 2. This indicates that the effect of Ziyin Xiezhuo prescription in lowering blood lipids in the treatment of postmenopausal women with coronary heart disease of kidney deficiency, blood stasis and phlegm turbidity type is equivalent to that of oral Western medicine + Liuwei Dihuang prescription.

[0022] There was no statistically significant difference in the total score of TCM syndromes between the control group and treatment group 1, treatment group 1 and treatment group 2 before treatment ( P >0.05), indicating that there was no significant difference in the total score of TCM syndromes between the two groups of patients before treatment, and they were comparable.

[0023] After treatment, the total score of TCM syndrome in the control group was (4.84±1.89), and the total score of TCM syndrome in the treatment group was (3.75±1.20). After paired sample t test, the total score of TCM syndrome in the two groups after treatment was (4.84±1.89). P The values ​​were all <0.01, and the differences between the two groups after treatment were statistically significant. The total scores of TCM syndromes in the two groups after treatment were compared by two independent sample t-tests. P =0.000( P <0.01), the difference was statistically significant. It means that both the control group and the treatment group 2 can improve the TCM symptoms, and the treatment group 2 is better than the control group. It shows that the Ziyin Xiezhuo prescription is significantly better than the simple Western medicine treatment group in improving TCM symptoms.

[0024] After treatment, the total score of TCM syndrome in treatment group 1 was (4.19±1.37), and the total score of TCM syndrome in treatment group 2 was (3.75±1.20). After paired sample t test, the total score of TCM syndrome in the two groups after treatment was (4.19±1.37), and the total score of TCM syndrome in treatment group 2 was (3.75±1.20). P The values ​​were all <0.01, and the differences between the two groups after treatment were statistically significant. The total scores of TCM syndromes in the two groups after treatment were compared by two independent sample t-tests. P =0.000 (P<0.01), the difference is statistically significant. It means that both treatment group 1 and treatment group 2 can improve TCM symptoms, and treatment group 2 is better than treatment group 1. It shows that the Ziyin Xiezhuo prescription is significantly better than the Western medicine + Liuwei Dihuang prescription group in improving TCM symptoms. See Table 1 and Table 2.

[0025] Table 1 Comparison of blood lipid levels and TCM syndrome scores before and after treatment in the control group and treatment group 2 (x±s)

[0026] Comparison of low-density lipoprotein and TCM syndrome scores between treatment group 1 and treatment group 2 before and after treatment (x±s)

[0027] 2. Comparison of estradiol and hs-CRP in the three groups before and after treatment There was no significant difference in estradiol and hs-CRP levels between the control group and treatment group 1, treatment group 1 and treatment group 2 before treatment ( P >0.05), indicating that the two groups of patients were comparable. After treatment, the control group had estradiol (24.16±11.25), hs-CRP (7.77±4.17), the treatment group had estradiol (35.54±9.48), hs-CRP (5.80±3.56), and the two groups had comparable results after treatment. P The values ​​were all <0.01, indicating that the differences between the two groups after treatment were statistically significant. The estradiol and hs-CRP indicators of the two groups after treatment were compared by two independent sample t tests. P =0.000( P <0.01), the difference was statistically significant. It means that both the control group and the treatment group 2 can increase the estrogen level and reduce the inflammatory index, and the treatment group 2 is better than the control group. It shows that the Ziyin Xiezhuo prescription is significantly better than the simple western medicine control group in improving the estrogen level and improving the inflammatory effect in the treatment of postmenopausal women with kidney deficiency, blood stasis and phlegm turbidity type coronary heart disease.

[0028] After treatment, the estradiol level in the treatment group I was (31.28±9.02), hs-CRP (7.21±3.79), and the estradiol level in the treatment group II was (35.54±9.48), hs-CRP (5.80±3.56). Paired sample t test showed that the two groups had a significant difference in estradiol level after treatment. P The values ​​were all <0.01, and the differences between the two groups after treatment were statistically significant. The estradiol and hs-CRP indicators of the two groups after treatment were compared by two independent sample t tests. P =0.00( P <0.05), the difference was statistically significant. This means that both treatment group 1 and treatment group 2 can increase estrogen levels and improve inflammation. This shows that the Ziyin Xiezhuo prescription is superior to the oral Western medicine + Liuwei Dihuang prescription group in increasing estrogen levels and improving inflammation in the treatment of postmenopausal women with kidney deficiency, blood stasis and phlegm turbidity type coronary heart disease. See Table 3 and Table 4.

[0029] Table 3 Comparison of estradiol and hs-CRP in the control group and treatment group 2 before and after treatment

[0030] Table 4 Comparison of estradiol and hs-CRP before and after treatment in treatment group 1 and treatment group 2

[0031] 3. Comparison of the efficacy of TCM syndromes among three groups In terms of the efficacy of TCM syndrome, the control group had 0 cases of marked effect, 5 cases of effective, and the total effective rate was 20%; the treatment group I had 4 cases of marked effect, 15 cases of effective, and the total effective rate was 76%; the treatment group II had 7 cases of marked effect, 16 cases of effective, and the total effective rate was 92%. This means that both the control group and the treatment group can improve TCM syndrome, and the treatment group II is better than the control group. This shows that the Ziyin Xiezhuo prescription is significantly better than the Western medicine treatment group alone and the Western medicine + Liuwei Dihuang prescription treatment group in improving the efficacy of TCM syndrome. (Table 5).

[0032] Table 5 Comparison of the efficacy of TCM syndromes among three groups

[0033] 3. Comparison of the incidence of adverse reactions between the two treatment groups There were 3 cases of adverse reactions in treatment group 1, all of which were digestive system symptoms. There was 1 case of adverse reactions in treatment group 2, also digestive system symptoms. This shows that the Ziyin Xiezhuo prescription is superior to the Western medicine + Liuwei Dihuang prescription treatment group in reducing the incidence of adverse reactions in the treatment of postmenopausal women with coronary heart disease of kidney deficiency, blood stasis and phlegm turbidity type. (Table 6) Table 6 Comparison of the incidence of adverse reactions between treatment group 1 and treatment group 2

[0034] 4. Prognosis After 6 weeks of medication, 10 people in treatment group 1 maintained stable blood lipid levels, and 15 people in treatment group 2 maintained normal blood lipid levels. This shows that the Ziyin Xiezhuo prescription is superior to the Western medicine + Liuwei Dihuang prescription treatment group in improving the prognosis of coronary heart disease in postmenopausal women with kidney deficiency, blood stasis and phlegm turbidity type.

[0035] Typical medical cases Case 1: Yang, female, 63 years old. Date of first visit: April 19, 2023. Chief complaint: chest tightness and shortness of breath after activity for 4 months. The patient has felt chest tightness and shortness of breath after activity for nearly 4 months. The symptoms are relieved after stopping the activity for a while, accompanied by soreness of waist and knees, fatigue, poor appetite, and loose stools. The blood lipid level LDL-C was checked in the outpatient clinic: 3.42mmol / L, and the electrocardiogram showed ST segment depression. The patient had a history of "hyperlipidemia" and had never taken medicine. After taking Western medicine + nourishing yin and purging turbidity prescription for 1 month, the blood lipid LDL-C was rechecked: 1.68mmol / L, estradiol: 34.17pmol•L-1, hs-CRP: 6.27mg•L-1. The patient's chest tightness symptoms were significantly relieved, and he did not complain of other discomforts such as soreness of waist and knees, fatigue, etc. His appetite was good and his stool was regular.

[0036] Case 2: Liu, female, 55 years old. Date of first visit: January 23, 2024. Chief complaint: chest tightness intermittent for 3 months, aggravated for 1 day. The patient experienced chest tightness and discomfort after activities 3 months ago, and the symptoms disappeared after resting for about 5 minutes, but she did not pay attention to it. One day ago, the chest tightness symptoms recurred in a quiet state, and could not be relieved after rest, accompanied by cold sweats, soreness of the waist and knees, and fatigue. The blood lipid level LDL-C was checked in the outpatient clinic: 4.12mmol / L, and the electrocardiogram showed ST segment depression. After taking Western medicine + nourishing yin and purging turbidity prescription for 2 months, the blood lipid LDL-C was rechecked: 1.81mmol / L, estradiol: 36.35pmol•L-1, hs-CRP: 5.18mg•L-1. The patient's chest tightness symptoms disappeared, the appetite was significantly improved, and there was no other discomfort such as soreness of the waist and knees.

[0037] in conclusion With the further exploration of the pharmacological effects of Chinese herbal medicine, the scope of modern diseases that Chinese herbal medicine can treat is getting wider and wider, and because Chinese medicine has little toxic and side effects, and the damage to liver and kidney function is lighter, the therapeutic advantage of Chinese medicine is more obvious. This prescription has the effects of nourishing yin and tonifying the kidney, resolving phlegm and removing blood stasis, and can improve the symptoms such as chest pain, chest tightness, soreness of waist and knees, irritability and night sweats caused by kidney deficiency, blood stasis and phlegm turbidity in postmenopausal female patients, and can reduce blood lipid levels at the same time, thereby reducing the probability of the occurrence and development of coronary heart disease in patients. The present invention is used in combination with traditional Western medicine to synergistically strengthen the lipid-lowering effect and improve the clinical symptoms of patients. The Chinese medicine prescription of the present invention is more scientific and reasonable, does not contain any chemical additives in the Chinese medicine prescription, has no side effects on the human body, and the prepared Chinese medicine medicament is not only simple to eat, easy to absorb, but also has good effects on tonifying the kidney and replenishing essence, resolving phlegm and removing blood stasis, promoting qi and activating blood circulation, dredge meridians and relieve pain, and lowering blood lipids, and can effectively improve the clinical symptoms of kidney deficiency, blood stasis and phlegm turbidity type coronary heart disease. In terms of dosage form, this invention uses modern process technology to concentrate the effective ingredients of various traditional Chinese medicines and prepare them into various dosage forms for easy administration.

Claims

1. A Chinese medicinal compound composition for treating coronary heart disease in postmenopausal women with kidney deficiency, blood stasis and phlegm turbidity, characterized in that: The invention comprises the following raw materials in parts by weight: 20-30 parts of Rehmannia root, 10-20 parts of Chinese yam, 5-15 parts of Cornus officinalis, 5-15 parts of Alisma orientalis, 10-20 parts of Paeonia suffruticosa, 10-20 parts of Poria cocos, 3-9 parts of Curcuma longa, 5-10 parts of Curcuma zedoariae, and 10-20 parts of Verbena officinalis.

2. A Chinese medicinal compound composition for treating coronary heart disease in postmenopausal women of kidney deficiency, blood stasis and phlegm turbidity type as claimed in claim 1, characterized in that: The mass proportions are 21-25 parts of Rehmannia root, 11-15 parts of Dioscorea opposita, 6-10 parts of Cornus officinalis, 6-10 parts of Alisma orientalis, 11-15 parts of Paeonia suffruticosa, 11-15 parts of Poria cocos, 4-6 parts of Curcuma longa, 6-9 parts of Curcuma zedoariae and 11-15 parts of Verbena officinalis.

3. A Chinese medicinal compound composition for treating coronary heart disease of postmenopausal women with kidney deficiency, blood stasis and phlegm turbidity type as claimed in claim 2, characterized in that: The following preparation method is adopted: put the raw material into a clean container, rinse it with clean water, remove the impurities on the surface and put it into the container, add 5 times the weight volume of water, boil it over high heat first, then decoct it over low heat for 1 to 2 hours, filter out the residue after the decocting is finished, and obtain the liquid medicine. Add the residue into the same amount of clean water as the first time again, and decoct it according to the above method, combine the liquid medicines obtained by the two decoctions, add ethanol with a volume concentration of 80%, let it stand, filter and recover it, and concentrate it at 60°C to a relative density of 1.30 to 1.36 to obtain an extract.

4. A Chinese medicinal compound composition for treating coronary heart disease of postmenopausal women with kidney deficiency, blood stasis and phlegm turbidity type as claimed in claim 3, characterized in that: The extract and a pharmaceutically acceptable carrier are prepared into a drug in the form of ointment, oral solution, granule, etc.

Images